Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test

SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight Psychotropic test.

“We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSight testing,” said Dale Muzzey, chief scientific officer, Myriad Genetics. “This is the first step in a multi-phase analysis of real-world data to further demonstrate how the GeneSight test may improve clinical outcomes and reduce overall healthcare costs. We expect to share additional study results later this year.”

The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing:

• 39% relative reduction in psychiatric-related hospitalizations.
• 29% relative reduction in hospitalizations for any reason.
• Significant reduction in hospitalizations for patients who were switched to a medication with no or moderate gene-drug interactions.
  

The study found that, among patients who took the GeneSight test, there was a decrease in the proportion of patients who were prescribed medications with significant gene-drug interactions after taking the test:

• The percentage of patients who were prescribed medications in the significant gene-drug interaction category was reduced from 26.1% to 15.9%.
• The percentage of patients who were prescribed medications with no gene-drug interactions increased from 27.5% to 47%.

“These data suggest that healthcare providers are using the GeneSight test to make medication decisions in the real-world,” said Holly Johnson, Ph.D, director of medical affairs at Myriad Genetics. “These results are consistent with multiple, prospective studies demonstrating the utility of pharmacogenomic-guided treatment for improving response and remission rates in major depressive disorder.”